Holen Sie sich die Stockscreener-App
7.22
1.83%
0.13
Handel nachbörslich:
7.40
0.18
+2.49%
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
SGMT Technical Analysis | Trend, Signals & Chart Patterns | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Why Are Analysts So Bullish on Sagimet Biosciences (SGMT) - Kavout
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade - Yahoo Finance
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
SGMT Maintained by Citizens -- Price Target Lowered to $12 - GuruFocus
Citizens cuts Sagimet Biosciences stock price target on valuation By Investing.com - Investing.com Nigeria
Sagimet Biosciences Is Maintained at Market Outperform by Citizens - Moomoo
Citizens JMP Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Citizens cuts Sagimet Biosciences stock price target on valuation - Investing.com
Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results - MSN
Sagimet Biosciences (SGMT) price target increased by 15.00% to 29.86 - MSN
Number of shareholders of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike - Stock Titan
Sagimet Biosciences (SGMT) files Form 3 identifying Chief Medical Officer Andreas Grauer - Stock Titan
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT) - Seeking Alpha
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target - TipRanks
TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewswire
Biotech Sagimet to give fireside chat at NASDAQ investor event - Stock Titan
Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Sagimet Biosciences reports first quarter 2026 financial results and provides corporate updates - marketscreener.com
Sagimet Biosciences Reports First Quarter 2026 Financial Results And Provides Corporate Updates - TradingView
Sagimet Biosciences Secures $175M Financing and Plans Phase 3 Denifanstat Acne Trial in 2026 - Minichart
Sagimet Biosciences 1Q Loss/Shr 33c >SGMT - Moomoo
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Sagimet Biosciences Inc. 1Q 2026: Net loss $(10.7)M, EPS $(0.33) — 10-Q Summary - TradingView
Sagimet Biosciences (NASDAQ: SGMT) trims Q1 2026 loss and raises $175M - Stock Titan
After 40-year wait, Sagimet backs Phase 3 test of new oral acne drug - Stock Titan
Sagimet Biosciences | 10-Q: Q1 2026 Earnings Report - Moomoo
Sagimet Biosciences (NASDAQ: SGMT) cuts R&D spend and raises $175M equity - Stock Titan
TradingKey - TradingKey
Sagimet Biosciences shares jump 30% on acne trial expansion plans - MSN
Targeting the Source: Sagimet's Novel Drug Aims to Revolutionize Acne Treatment - BriefGlance
Does Sagimet Biosciences Inc. (SGMT) have the potential to rally 241.77% as Wall Street analysts expect? - MSN
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society ... - Caledonian Record
Sagimet Biosciences to Present Mechanism of Action Data for - GlobeNewswire
Lab data back Sagimet’s experimental acne approach before Phase 3 trial - Stock Titan
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - sharewise.com
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect? - Yahoo Finance
Sagimet Biosciences Price Target Raised to $49.00/Share From $28.00 by Canaccord Genuity - Moomoo
Sagimet Biosciences Is Maintained at Buy by Canaccord Genuity - Moomoo
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $31 - Moomoo
CCORF Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $49 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sagimet Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):